US FDA Declines to Approve Merck’s Chronic Cough Drug
(Reuters) -The U.S. Food and Drug Administration (FDA) declined to approve Merck's drug for chronic cough, the company said on ...
(Reuters) -The U.S. Food and Drug Administration (FDA) declined to approve Merck's drug for chronic cough, the company said on ...
(Reuters) -The U.S. Food and Drug Administration (FDA) granted full approval to Swedish drugmaker Calliditas Therapeutics' drug to treat rare ...
Share on PinterestConcerns over salmonella risk have prompted Quaker Oats officials to issue a product recall. Tim Boyle/Newsmakers/Getty ImagesQuaker Oats ...
Vegan burgers, sausages and mince are often made from textured soya protein, a highly processed ingredientdropStock/Shutterstock Health-conscious vegans may face ...
PARIS (Reuters) - Drugmaker Servier must pay more than 430 million euros ($471 million) in connection with weight-loss pill Mediator, ...
Keep an eye on those champagne corks this holiday season -- but not too close an eye, researchers warned. Eye ...
A new study in the annual BMJ Christmas issue suggests high levels of unprotected sex during New Year's Eve celebrations ...
TOPLINE:After the elimination of the mandatory training required to prescribe buprenorphine for opioid use disorder, prescriptions for the drug declined ...
A scanning electron micrograph of mammalian embryonic stem cellsYORGOS NIKAS/SCIENCE PHOTO LIBRARY The chemical reactions that cells use to power ...
(Reuters) - More than 15.3 million Americans have signed up for health insurance under the Affordable Care Act (ACA) for ...
Three patients diagnosed with melioidosis in a Mississippi Gulf Coast county probably picked up the disease from the local environment, ...
Doxycycline postexposure prophylaxis (PEP) up to 72 hours after unprotected sex did not prevent sexually transmitted infections (STIs) in cisgender ...
Roy-Bornstein is a writer and a retired pediatrician. Last week, Massachusetts hospitals, local health plans, and healthcare systems all committed ...
The FDA approved the first test that uses DNA to identify whether adults have an elevated risk of developing opioid ...
Jean-Philippe Collet, MD, head of medical cardiology at Pitié-Salpêtrière Hospital, Paris, France, passed away suddenly on Friday, December 15, at ...
Mosunetuzumab (Lunsumio) is a first-in-class bispecific antibody that last year received accelerated approval for relapsed or refractory follicular lymphoma. At ...
Stopping long-term benzodiazepine treatment was tied to a higher risk of death, according to a comparative effectiveness study using claims ...
In a pivotal phase II study, the investigational bispecific antibody odronextamab demonstrated clinically meaningful efficacy in patients with relapsed or ...
TOPLINE:Removing race and incorporating social determinants of health (SDOH) into the pooled cohort risk equations (PCEs) for predicting atherosclerotic cardiovascular ...
Covid and other infections could rise in many parts of the world this winter, the experts warn. Source link : ...
© 2022 NewsHealth.
© 2022 NewsHealth.
JN.1 Covid variant: WHO charts its rapid global spread- JN.1 Covid variant: WHO charts its rapid global spread * JN.1 Covid variant: WHO charts its rapid global spread | JN.1 Covid variant: WHO charts its rapid global spread | JN.1 Covid variant: WHO charts its rapid global spread | JN.1 Covid variant: WHO charts its rapid global spread | JN.1 Covid variant: WHO charts its rapid global spread | JN.1 Covid variant: WHO charts its rapid global spread | JN.1 Covid variant: WHO charts its rapid global spread | JN.1 Covid variant: WHO charts its rapid global spread | | JN.1 Covid variant: WHO charts its rapid global spread | | JN.1 Covid variant: WHO charts its rapid global spread | | JN.1 Covid variant: WHO charts its rapid global spread |
NEWSHEALTH : JN.1 Covid variant: WHO charts its rapid global spread